James C Tsai

Dr. James C Tsai


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
SSSophia Mirza Saleem
Sophia Mirza Saleem
LPLouis R. Pasquale
Louis R. Pasquale
PSPaul A. Sidoti
Paul A. Sidoti
JTJames C Tsai
James C Tsai

10 April 2020 in Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
JTJames C Tsai
James C Tsai
While sustained reduction of intraocular pressure (IOP) has been shown to halt and/or delay the progressive death of retinal ganglion cells (RGCs) in glaucoma, there exists great interest in the development and validation of IOP-independent therapeutic strategies for neuroprotection and/or neuroregeneration. Multiple etiologies for RGC death have been implicated in glaucoma including defective axonal transport, ischemia, excitotoxicity, reactive oxygen species, trophic factor withdrawal, and loss of RGC electrical activity. However, IOP lowering with medical, laser, and surgical therapies is itself neuroprotective, and investigators are seeking to identify agents that are able to confer neuroprotection independent of IOP reduction, as well as providing for regeneration of nonviable RGCs and their axons to restore and/or maintain functional vision. These innovative strategies in the pipeline include investigation of neurotrophic factors, gene therapy, immune system modulation, and novel neuroregeneration pathways. Alongside this new knowledge, enhanced opportunities for discovery of vision preservation and/or restoration therapies must be weighed against the potential disadvantages of perturbing the complex central nervous system environment.

1 February 2019 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
NCNisha Chadha
Nisha Chadha
JWJoshua L. Warren
Joshua L. Warren
JLJi Liu
Ji Liu
JTJames C Tsai
James C Tsai
CTChristopher C. Teng
Christopher C. Teng
Purpose: This study evaluated US resident and fellow glaucoma surgical experience over a 7- and 8-year period, respectively. Methods: US ophthalmology resident glaucoma case logs from 2009 to 2016 and glaucoma fellow case logs from 2008 to 2016 were reviewed. The number of total, average, median, and minimum cases, along with percentile data for filtering surgery, shunting surgery, and novel procedures were analyzed for year-to-year trends. Results: Among residents training from 2009 to 2016, there was a decline in the average number of primary filtering surgeries by 20%, from 6.0±5.0 to 4.8±4.0 cases, with a concurrent increase in average primary glaucoma drainage implant (GDI) surgeries by 40%, from 4.5±4.0 to 6.3±5.0 cases, which represented an increase of 6.5% per year, P<0.001. Glaucoma fellow data from 2008 to 2015 demonstrated a decline in average primary trabeculectomy surgeries by 3.7%, from 30.1 to 29.0 cases, but then increased to 32.1 cases in 2015–2016. There was an increase in average GDI surgeries by 57.9%, from 30.2 to 47.7 cases for fellows over this 8-year period, which represented a 5.9% increase per year, P<0.001. There was no microinvasive glaucoma surgery (MIGS) or other novel procedures reported in the Accreditation Council for Graduate Medical Education (ACGME) resident case logs. From 2008 to 2016, Association of University Professors of Ophthalmology (AUPO) glaucoma fellow case logs demonstrated an increase in endocyclophotocoagulation (ECP) from 2.3 to 5.4 cases, a 15.5% increase per year, P<0.001. Conclusions: Over a 7–8-year period, trainee surgical experience with GDI surgery has steadily increased, whereas surgical experience with trabeculectomy has been fluctuating and may be on a downward trend. Educators should be aware of shifts in trainee surgical experience in order to maintain appropriate training experience.

4 August 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SWSze Wong
Sze Wong
JTJames C Tsai
James C Tsai
Telehealth has become a viable option for glaucoma screening and glaucoma monitoring due to advances in technology. The ability to measure intraocular pressure without an anesthetic and to take optic nerve photographs without pharmacologic pupillary dilation using portable equipment have allowed glaucoma screening programs to generate enough data for assessment. At home, patients can perform visual acuity testing, web-based visual field testing, rebound tonometry, and video visits with the physician to monitor for glaucomatous progression. Artificial intelligence will enhance the accuracy of data interpretation and inspire confidence in popularizing telehealth for glaucoma.

1 November 2018 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
LPLouis Pasquale
Louis Pasquale
SLShan Lin
Shan Lin
RWRobert N Weinreb
Robert N Weinreb
JTJames C Tsai
James C Tsai
RKRobert L Kramm
Robert L Kramm
TITsontcho Ianchulev
Tsontcho Ianchulev
Background: Topical high-precision piezo-print delivery of microdoses of latanoprost achieved significant IOP reduction consistent with the eyedropper effect but with a 75% reduced exposure to drugs and preservatives. Prostaglandin analogs are a mainstay glaucoma therapy. However, conventional eyedroppers deliver 30–50 μL drops that greatly exceed the physiologic 7-μL ocular tear film capacity. Eyedropper overdosing floods the eye with excess drug compounds and preservatives, resulting in ocular surface toxicity, periorbitopathy, and other well-characterized ocular side effects. Piezoelectric high-precision microdosing provides targeted delivery that can reduce exposure to both drug and preservatives compared to conventional eyedropper delivery, with the potential to deliver similar biologic effect. Methods: Both eyes (N=60) of 30 healthy volunteers received single 8-μL microdoses of 0.005% latanoprost (0.4 μg; μRx-latanoprost) on the morning of Days 1 and 2 using a high-precision, piezo-print horizontal delivery system. Diurnal IOP was measured before and 2 days after microdosing. Main efficacy outcomes were diurnal IOP change after μRx-latanoprost microdosing and accurate microdosing success rates, and the primary safety outcome was adverse event (AE) incidence. Results: μRx-latanoprost reduced baseline IOP by 26% and 30% at 1 and 2 days postadministration, respectively. Successful topical dosing was achieved in 100% of technician-assisted deliveries. All patients successfully self-administered microdoses after receiving training. Microdose administration was well tolerated and did not result in any AEs. Conclusion: Microdosing of 0.4 μg of μRx-latanoprost achieved significant IOP reduction. Lower ocular exposure with topical prostaglandin analog microdosing can enable new therapeutic opportunities for optimizing glaucoma treatment. Microdosing may also be beneficial in reducing ocular side effects associated with excessive drug product and preservatives often used to treat chronic ocular diseases such as glaucoma.

28 July 2016 in Health Services Research
Verified
Journal Article
Closed access
PDF file
DGDan Gong
Dan Gong
LJLin Jun
Lin Jun
JTJames C Tsai
James C Tsai